| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/02/2002 | US6365611 Pentaerythrite derivatives, the production and use thereof and intermediate products for the synthesis of the same |
| 04/02/2002 | US6365609 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 04/02/2002 | US6365607 Thiazolidinedione and oxazolidinedione compounds for treatment of diabetic anemia, edema, and anorexia |
| 04/02/2002 | US6365605 Substituted hydrochromenopyrroles |
| 04/02/2002 | US6365603 Aromatic compounds and pharmaceutical compositions containing them |
| 04/02/2002 | US6365602 For therapy of depression, anxiety, asthma, pain, inflammation, urinary incontinence and other disease conditions |
| 04/02/2002 | US6365600 For therapy of condition associated with smooth muscle cell proliferation in a warm-blooded animal which comprises administering imidazol-5-yl-methyl-2-quinolinone derivatives |
| 04/02/2002 | US6365598 Pyrroloquinolines for treatment of obesity |
| 04/02/2002 | US6365594 As opioid agonists and antagonists and are useful as i.a. analgesics |
| 04/02/2002 | US6365587 Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 04/02/2002 | US6365579 Nitrate esters and their use for neurological conditions |
| 04/02/2002 | US6365577 Administering to the subject, in a suitable pharmaceutical carrier, a pharmaceutically effective amount of an antisense agent which is morpholino oligonucleotide for inhibiting expression of p53 |
| 04/02/2002 | US6365575 Gene delivery and expression in areas inaccessible to direct protein delivery |
| 04/02/2002 | US6365572 For therapy of diseases related to increased or unwanted synthesis of basement membranes such as diabetes mellitus; atherosclerosis; cancer; diabetic retinopathia; fibroplasia retrolentalis; or psoriasis, rheumatoic arthritis |
| 04/02/2002 | US6365571 FGF inhibitor, angiogenesis inhibitor and antitumor agent containing complestatin or its derivative as effective ingredient |
| 04/02/2002 | US6365414 Vitro system for determining formation of Aβ amyloid |
| 04/02/2002 | US6365402 Growth differentiation factor-9 |
| 04/02/2002 | US6365393 Recombinant virus with an insertion in the hind iii fragment i region; immunomodulators |
| 04/02/2002 | US6365391 Isolated human serine protease, nucleic acid molecules encoding human serine protease, and uses thereof |
| 04/02/2002 | US6365389 Human protein kinase H2LAU20 |
| 04/02/2002 | US6365365 Method of determining whether an agent modulates glycosyl sulfotransferase-3 |
| 04/02/2002 | US6365359 Identifying prp pharmacore by determining functional residues of protein involved in complex interactions, developing three dimensional structures, comparing them with other compounds and identifying compounds consistent with binding to protein |
| 04/02/2002 | US6365159 Spo-rel |
| 04/02/2002 | US6365154 Tie2 agonist antibodies |
| 04/02/2002 | US6365135 Bleaching human skin, hair |
| 04/02/2002 | CA2357929A1 Nmda nr2b antagonists for the treatment of depression |
| 04/02/2002 | CA2357925A1 Prophylactic use of n-methyl-d-asparate (nmda) antagonists |
| 04/02/2002 | CA2144047C Method and compositions for maintaining glomerular filtration rate while inhibiting extracellular matrix accumulation |
| 04/02/2002 | CA2099868C Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines |
| 04/02/2002 | CA2053340C Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| 03/28/2002 | WO2002024924A2 Protein phosphatases |
| 03/28/2002 | WO2002024920A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/28/2002 | WO2002024910A2 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof |
| 03/28/2002 | WO2002024892A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding them, and uses thereof |
| 03/28/2002 | WO2002024891A2 B7-like molecules and uses thereof |
| 03/28/2002 | WO2002024887A2 Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| 03/28/2002 | WO2002024751A1 Dextran-hemoglobin conjugates as blood substitutes |
| 03/28/2002 | WO2002024749A2 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof |
| 03/28/2002 | WO2002024748A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/28/2002 | WO2002024727A2 New inhibitors of iapp fibril formation and uses thereof |
| 03/28/2002 | WO2002024726A2 Olfactory and pheromones g-protein coupled receptors |
| 03/28/2002 | WO2002024717A1 Antisense modulation of flip-c expression |
| 03/28/2002 | WO2002024715A2 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
| 03/28/2002 | WO2002024711A1 Novel thiazole bicyclic compounds |
| 03/28/2002 | WO2002024708A1 Prodrugs of a 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotic |
| 03/28/2002 | WO2002024705A1 Stereoselective process for preparing cyclohexyl amine derivatives |
| 03/28/2002 | WO2002024703A1 Bicyclic heteroaromatic compounds |
| 03/28/2002 | WO2002024702A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | WO2002024701A2 Substituted azepino[4,5b)indole derivatives |
| 03/28/2002 | WO2002024700A2 SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES |
| 03/28/2002 | WO2002024698A1 Xanthine phosphodiesterase v inhibitors |
| 03/28/2002 | WO2002024697A1 Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient |
| 03/28/2002 | WO2002024695A2 Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines |
| 03/28/2002 | WO2002024694A1 Pyrazolopyridines and pyrazolopyridazines as antidiabetics |
| 03/28/2002 | WO2002024693A1 A process for producing 3,4-dihydro naphthyridinone analogs |
| 03/28/2002 | WO2002024687A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
| 03/28/2002 | WO2002024686A2 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
| 03/28/2002 | WO2002024683A1 Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives |
| 03/28/2002 | WO2002024682A1 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
| 03/28/2002 | WO2002024681A2 Pyrazine derivatives as modulators of tyrosine kinases |
| 03/28/2002 | WO2002024680A1 Imidazole derivatives as raf kinase inhibitors |
| 03/28/2002 | WO2002024679A1 PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY |
| 03/28/2002 | WO2002024674A1 Benzoic acid derivatives and uses thereof |
| 03/28/2002 | WO2002024672A2 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 03/28/2002 | WO2002024667A1 4-amino-quinazolines |
| 03/28/2002 | WO2002024666A2 4-amino-quinazolines |
| 03/28/2002 | WO2002024665A1 Arylalkane-sulfonamides having endothelin-antagonist activity |
| 03/28/2002 | WO2002024662A1 New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
| 03/28/2002 | WO2002024661A2 New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
| 03/28/2002 | WO2002024659A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists |
| 03/28/2002 | WO2002024653A1 Compounds and methods for modulation of estrogen receptors |
| 03/28/2002 | WO2002024651A1 A process for producing 2-amino-4,6-disubstituted nicotinic acid ester analogs |
| 03/28/2002 | WO2002024649A1 Substituted amino-aza-cycloalkanes useful against malaria |
| 03/28/2002 | WO2002024647A1 Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| 03/28/2002 | WO2002024641A1 Tricyclic indole compounds having affinity for serotonin receptor |
| 03/28/2002 | WO2002024633A1 Phenylpropionic acid derivatives |
| 03/28/2002 | WO2002024632A2 Substituted aminopropoxyaryl derivatives useful as agonists for lxr |
| 03/28/2002 | WO2002024630A1 Pharmaceutical compounds useful as modulators of endocannabinoid-mediated response |
| 03/28/2002 | WO2002024229A1 Method of regulating osteoclast formation |
| 03/28/2002 | WO2002024228A1 Method of regulating osteoclast formation |
| 03/28/2002 | WO2002024219A1 Growth factor complex |
| 03/28/2002 | WO2002024218A1 Angiogenic agents and their uses |
| 03/28/2002 | WO2002024217A1 Use of il-8 protein modulators in the treatment of viral infections |
| 03/28/2002 | WO2002024204A2 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter |
| 03/28/2002 | WO2002024200A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| 03/28/2002 | WO2002024197A1 Fatty acid synthase inhibitors |
| 03/28/2002 | WO2002024189A1 Cell activator |
| 03/28/2002 | WO2002024187A2 Treatment of diseases with adamantane derivatives |
| 03/28/2002 | WO2002024180A2 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| 03/28/2002 | WO2002024179A2 Method for reducing toxicity of combined chemotherapies |
| 03/28/2002 | WO2002023990A1 Disinfectant |
| 03/28/2002 | WO2002009651A3 Fatty acid synthase inhibitors |
| 03/28/2002 | WO2002000679A3 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group |
| 03/28/2002 | WO2002000266A3 A method of treating and preventing infectious diseases |
| 03/28/2002 | WO2001097751A3 New formulation comprising a betablocker and optionally a cholesterol-lowering agent |
| 03/28/2002 | WO2001096336A3 6,5-fused bicyclic heterocycles |
| 03/28/2002 | WO2001094952A3 Methods and compositions for modulating oxidized ldl transport |
| 03/28/2002 | WO2001090106A3 Tryasolyl tropane derivatives as ccr5 modulators |
| 03/28/2002 | WO2001085762B1 Cancer diagnosis and assays for screening anti-cancer agents |
| 03/28/2002 | WO2001085169A3 R-eliprodil for treating glaucoma |